Literature DB >> 10882211

Systemic sclerosis (scleroderma) and related disorders: clinical aspects.

P J Clements1.   

Abstract

To adequately evaluate and manage patients with systemic sclerosis, practitioners and patients alike must have a working knowledge of the natural history of the disease. What we know generally about the natural history should be coupled with four pieces of patient specific clinical information. (i) Does the patient have systemic sclerosis? (ii) How long has the patient had systemic sclerosis? (iii) How extensive was/is the sclerodermatous skin induration/ thickening at its worst? (iv) Is there presently evidence of visceral involvement (heart, lung, kidney, gastrointestinal, musculoskeletal)? This chapter will show you how to use this information to construct (for you and the patient) a picture of where that patient is presently in the natural history, where the patient is likely to be in the future (in general terms), what visceral involvements are likely or unlikely to occur, what evaluations are needed now and in the future, and what treatments are recommended and why.

Entities:  

Mesh:

Year:  2000        PMID: 10882211     DOI: 10.1053/berh.1999.0074

Source DB:  PubMed          Journal:  Baillieres Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  11 in total

1.  Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis.

Authors:  Dinesh Khanna; Daniel E Furst; Weng Kee Wong; Joel Tsevat; Philip J Clements; Grace S Park; Arnold E Postlethwaite; Mansoor Ahmed; Shaari Ginsburg; Ron D Hays
Journal:  Qual Life Res       Date:  2007-04-03       Impact factor: 4.147

2.  Feasibility and construct validity of PROMIS and "legacy" instruments in an academic scleroderma clinic.

Authors:  Dinesh Khanna; Paul Maranian; Nan Rothrock; David Cella; Richard Gershon; Puja P Khanna; Brennan Spiegel; Daniel E Furst; Phil J Clements; Amber Bechtel; Ron D Hays
Journal:  Value Health       Date:  2011-10-22       Impact factor: 5.725

3.  Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise.

Authors:  Jaap Fransen; Sindhu R Johnson; Frank van den Hoogen; Murray Baron; Yannick Allanore; Patricia E Carreira; László Czirják; Christopher P Denton; Oliver Distler; Daniel E Furst; Armando Gabrielli; Ariane Herrick; Murat Inanc; Bashar Kahaleh; Otylia Kowal-Bielecka; Thomas A Medsger; Ulf Mueller-Ladner; Gabriela Riemekasten; Stanislaw Sierakowski; Gabriele Valentini; Doug Veale; Madelon C Vonk; Ulrich Walker; Lorinda Chung; Philip J Clements; David H Collier; Mary E Csuka; Sergio Jimenez; Peter A Merkel; James R Seibold; Richard Silver; Virginia Steen; Alan Tyndall; Marco Matucci-Cerinic; Janet E Pope; Dinesh Khanna
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-03       Impact factor: 4.794

Review 4.  Systemic sclerosis: commonly asked questions by rheumatologists.

Authors:  Amber Young; Dinesh Khanna
Journal:  J Clin Rheumatol       Date:  2015-04       Impact factor: 3.517

5.  Musculoskeletal ultrasound of the shoulder in systemic sclerosis.

Authors:  Vatakan Surat; Patpiya Sirasaporn; Chingching Foocharoen
Journal:  J Scleroderma Relat Disord       Date:  2022-04-10

6.  What is the relationship between disease activity, severity and damage in a large Canadian systemic sclerosis cohort? Results from the Canadian Scleroderma Research Group (CSRG).

Authors:  Xiangning Fan; Janet Pope; Murray Baron
Journal:  Rheumatol Int       Date:  2009-09-24       Impact factor: 2.631

7.  Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study.

Authors:  D Khanna; D E Furst; R D Hays; G S Park; W K Wong; J R Seibold; M D Mayes; B White; F F Wigley; M Weisman; W Barr; L Moreland; T A Medsger; V D Steen; R W Martin; D Collier; A Weinstein; E V Lally; J Varga; S R Weiner; B Andrews; M Abeles; P J Clements
Journal:  Ann Rheum Dis       Date:  2006-03-15       Impact factor: 19.103

8.  Radical oxygen species production induced by advanced oxidation protein products predicts clinical evolution and response to treatment in systemic sclerosis.

Authors:  A Servettaz; P Guilpain; C Goulvestre; C Chéreau; C Hercend; C Nicco; L Guillevin; B Weill; L Mouthon; F Batteux
Journal:  Ann Rheum Dis       Date:  2007-03-15       Impact factor: 19.103

Review 9.  The heart in scleroderma.

Authors:  Hunter C Champion
Journal:  Rheum Dis Clin North Am       Date:  2008-02       Impact factor: 2.670

10.  Valuation of scleroderma and psoriatic arthritis health states by the general public.

Authors:  Dinesh Khanna; Tracy Frech; Puja P Khanna; Robert M Kaplan; Mark H Eckman; Ron D Hays; Shaari S Ginsburg; Anthony C Leonard; Joel Tsevat
Journal:  Health Qual Life Outcomes       Date:  2010-10-01       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.